Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kevin K W Olesen"'
Autor:
Tomas Jernberg, David Erlinge, Michael Maeng, Margret Leosdottir, Joakim Alfredsson, Peter Vasko, Philippe Wagner, Jonas Carlson, Rebecca Tremain Rylance, Kevin K W Olesen, Pelle Johansson, Moman Aladdin Mohammed
Publikováno v:
Open Heart, Vol 9, Iss 2 (2022)
Objectives Our aim was to derive, based on the SWEDEHEART registry, and validate, using the Western Denmark Heart registry, a patient-oriented risk score, the SweDen score, which could calculate the risk of 1-year mortality following a myocardial inf
Externí odkaz:
https://doaj.org/article/c3742f74be6447d787f1af913a07a29f
Autor:
Esben Laugesen, Kevin K. W. Olesen, Christian Daugaard Peters, Niels Henrik Buus, Michael Maeng, Hans Erik Botker, Per L. Poulsen
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 10 (2022)
Background Estimated pulse wave velocity (ePWV) calculated by equations using age and blood pressure has been suggested as a new marker of mortality and cardiovascular risk. However, the prognostic potential of ePWV during long‐term follow‐up in
Externí odkaz:
https://doaj.org/article/65d3d719d23b4800a1e62e6af3edba21
Autor:
Thomas Jensen, Pernille G Thrane, Kevin K W Olesen, Morten Würtz, Martin Bødtker Mortensen, Christine Gyldenkerne, Troels Thim, Bjarne Linde Nørgaard, Jesper Møller Jensen, Steen Dalby Kristensen, Jens C Nielsen, John W Eikelboom, Michael Maeng
Publikováno v:
Jensen, T, Thrane, P G, Olesen, K K W, Würtz, M, Mortensen, M B, Gyldenkerne, C, Thim, T, Nørgaard, B L, Jensen, J M, Kristensen, S D, Nielsen, J C, Eikelboom, J W & Maeng, M 2023, ' Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation ', European heart journal. Cardiovascular pharmacotherapy, vol. 9, no. 3, 208-219 . https://doi.org/10.1093/ehjcvp/pvac058
Aims Beyond 1 year after percutaneous coronary intervention (PCI), guidelines recommend anticoagulant monotherapy in patients with atrial fibrillation (AF) rather than dual therapy with an anticoagulant and an antiplatelet drug. The risks and benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7add3fd87c25fefd581498b0774066c2
https://pure.au.dk/portal/da/publications/antithrombotic-treatment-beyond-1-year-after-percutaneous-coronary-intervention-in-patients-with-atrial-fibrillation(9eb5a09e-3167-42a4-abfa-095dd6fb12e6).html
https://pure.au.dk/portal/da/publications/antithrombotic-treatment-beyond-1-year-after-percutaneous-coronary-intervention-in-patients-with-atrial-fibrillation(9eb5a09e-3167-42a4-abfa-095dd6fb12e6).html
Autor:
Rebecca Tremain, Rylance, Philippe, Wagner, Kevin K W, Olesen, Jonas, Carlson, Joakim, Alfredsson, Tomas, Jernberg, Margret, Leosdottir, Pelle, Johansson, Peter, Vasko, Michael, Maeng, Moman Aladdin, Mohammed, David, Erlinge
Publikováno v:
Open heart. 9(2)
Our aim was to derive, based on the SWEDEHEART registry, and validate, using the Western Denmark Heart registry, a patient-oriented risk score, the SweDen score, which could calculate the risk of 1-year mortality following a myocardial infarction (MI
Autor:
Rebecca T. Rylance, Philippe Wagner, Kevin K. W. Olesen, Jonas Carlson, Joakim Alfredsson, Tomas Jernberg, Margret Leosdottir, Pelle Johansson, Peter Vasko, Michael Maeng, Moman A. Mohammad, David Erlinge
ObjectivesOur aim was to derive, based on the SWEDEHEART registry, and validate, using the Western Denmark Heart registry, a patient-oriented risk score, the SweDen score, which could calculate the risk of 1-year mortality following a myocardial infa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af7a7c7fbb55d7176f24694db5f68206
https://doi.org/10.1101/2022.09.14.22279852
https://doi.org/10.1101/2022.09.14.22279852
Publikováno v:
Kristensen, S D, Olesen, K K W & Maeng, M 2022, ' The end of aspirin for dementia prevention in diabetes? ', European Heart Journal, vol. 43, no. 21, pp. 2020-2022 . https://doi.org/10.1093/eurheartj/ehac211
Autor:
Moman A Mohammad, Kevin K W Olesen, Sasha Koul, Chris P Gale, Rebecca Rylance, Tomas Jernberg, Tomasz Baron, Jonas Spaak, Stefan James, Bertil Lindahl, Michael Maeng, David Erlinge
Publikováno v:
Mohammad, M A, Olesen, K K W, Koul, S, Gale, C P, Rylance, R, Jernberg, T, Baron, T, Spaak, J, James, S, Lindahl, B, Maeng, M & Erlinge, D 2022, ' Development and validation of an artificial neural network algorithm to predict mortality and admission to hospital for heart failure after myocardial infarction : a nationwide population-based study ', The Lancet. Digital health, vol. 4, no. 1, pp. e37-e45 . https://doi.org/10.1016/S2589-7500(21)00228-4
BACKGROUND: Patients have an estimated mortality of 15-20% within the first year following myocardial infarction and one in four patients who survive myocardial infarction will develop heart failure, severely reducing quality of life and increasing t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37fcfc0db46686031f708516e8752cd8
https://pure.au.dk/portal/da/publications/development-and-validation-of-an-artificial-neural-network-algorithm-to-predict-mortality-and-admission-to-hospital-for-heart-failure-after-myocardial-infarction(7e65a3be-af8b-447d-bcc8-cc60081bdb2c).html
https://pure.au.dk/portal/da/publications/development-and-validation-of-an-artificial-neural-network-algorithm-to-predict-mortality-and-admission-to-hospital-for-heart-failure-after-myocardial-infarction(7e65a3be-af8b-447d-bcc8-cc60081bdb2c).html
Autor:
Marie V, Hjortbak, Kevin K W, Olesen, Jacob M, Seefeldt, Thomas R, Lassen, Rebekka V, Jensen, Alexander, Perkins, Matthew, Dodd, Tim, Clayton, Derek, Yellon, Derek J, Hausenloy, Hans Erik, Bøtker
Publikováno v:
Basic Research in Cardiology
We studied the translational cardioprotective potential of P2Y